NASA Light Emitting Diode Medical
Applications
From Deep Space to Deep Sea
Harry T. Whelan1a,5,7, Ellen V.
Buchmann1a,
Noel T. Whelan1a,7, Scott G. Turner1a,
Vita Cevenini7, Helen Stinson7, Ron Ignatius2, Todd Martin2,
Joan Cwiklinski1a, Glenn A. Meyer1c, Brian Hodgson3,4, Lisa
Gould1b,
Mary Kane1b, Gina Chen1b, James Caviness6
1aDepartments of Neurology, 1bPlastic
Surgery, 1cNeurosurgery,
Medical College of Wisconsin, Milwaukee, WI 53226, (414)
456-4090
2Quantum Devices, Inc Barneveld, WI 53507 (608) 924-3000
3Children’s Hospital of Wisconsin, Milwaukee, WI 53201 (414)
266-2044
44th Dental Battalion, 4th Force Service Support Group,
USMCR, Marietta, GA
5Naval Special Warfare Group TWO, Norfolk, VA 23521, (757)
462-7759
6Submarine Squadron ELEVEN, San Diego, CA 92106,
(619)553-8719
7NASA-Marshall Space Flight Center, AL 35812, (256) 544-2121
Abstract:
This work is supported and managed through
the NASA Marshall Space Flight Center - SBIR Program.
LED-technology developed for NASA plant growth experiments
in space shows promise for delivering light deep into
tissues of the body to promote wound healing and human
tissue growth. We present the results of LED-treatment of
cells grown in culture and the effects of LEDs on patients'
chronic and acute wounds. LED-technology is also
biologically optimal for photodynamic therapy of cancer and
we discuss our successes using LEDs in conjunction with
light-activated chemotherapeutic drugs.
We have all heard how space technology can
benefit us all here on earth; well this is no exception when
we look at LED therapy. While the researchers in the field
were fine-tuning their devices for pain relief, NASA needed
a means to produce light without the added heat produced by
incandescent light bulbs for space missions and their plant
experiments. NASA settled on (LED’s) because of their
ability to produce a scattered light of various wavelengths
that were of benefit to plants in the confinements of a
space vehicle in space flight, while producing no
significant increase in thermal heat. They worked, and NASA
took the next step. Could LED’s help in healing injuries to
astronauts while in space flight. One of the major dilemmas
for NASA regarding long-term space flight is the
well-documented effect of muscle and bone atrophy that
occurs to astronauts while in space. In addition it has been
shown that injuries that occur while in space tend not to
heal until the astronaut is back within the earth’s
gravity. The LED’s that produced near-infrared light used
in NASA’s research were shown to stimulate the basic energy
processes by activating color sensitive chemicals within the
cells. DNA synthesis in fibroblasts and muscle cells had
been quintupled. The light absorbed by the cells stimulated
the metabolism in muscle and bone as well as skin and
subcutaneous tissue. What people and animals had felt
through utilizing this technology in real life, NASA was
proving to be true in the laboratory.
LED-ENHANCEMENT OF CELL GROWTH
Studies on cells exposed to microgravity
and hypergravity indicate that human cells need gravity to
stimulate growth. As the gravitational force increases or
decreases, the cell function responds in a linear fashion.
This poses significant health risks for astronauts in
long-term space flight. The application of light therapy
with the use of NASA LEDs will significantly improve the
medical care that is available to astronauts on long-term
space missions. NASA LEDs stimulate the basic energy
processes in the mitochondria (energy compartments) of each
cell, particularly when near-infrared light is used to
activate the color sensitive chemicals (chromospheres,
cytochrome systems) inside. Optimal LED wavelengths include
680, 730 and 880 nm and their laboratory has improved the
healing of wounds in laboratory animals by using both LED
light and hyperbaric oxygen. Furthermore, DNA synthesis in
fibroblasts and muscle cells has been quintupled using NASA
LED light alone, in a single application combining 680, 730
and 880 nm each at 4 Joules per centimeter squared.
Muscle and bone atrophy are well
documented in astronauts, and various minor injuries
occurring in space have been reported not to heal until
landing on Earth. An LED blanket device may be used for the
prevention of bone and muscle atrophy in astronauts. The
depth of near-infrared light penetration into human tissue
has been measured spectroscopically (Chance, et al., 1988).
Spectra taken from the wrist flexor muscles in the forearm
and muscles in the calf of the leg demonstrate that most of
the light photons at wavelengths between 630-800 nm travel
23 cm through the surface tissue and muscle between input
and exit at the photon detector. The light is absorbed by
mitochondria where it stimulates energy metabolism in muscle
and bone, as well as skin and subcutaneous tissue.
Long term space flight, with its many
inherent risks, also raises the possibility of astronauts
being injured performing their required tasks. The fact
that the normal healing process is negatively affected by
microgravity requires novel approaches to improve wound
healing and tissue growth in space. NASA LED arrays have
already flown on Space Shuttle missions for studies of plant
growth and the U.S. Food and Drug Administration (FDA) has
approved human trials. The use of light therapy with LEDs
can help prevent bone and muscle atrophy as well as increase
the rate of wound healing in a microgravity environment,
thus reducing the risk of treatable injuries becoming
mission catastrophes.
Space flight has provided a laboratory for
studying wound healing problems due to microgravity, which
mimic traumatic wound healing problems here on earth.
Improved wound healing may have multiple applications that
benefit civilian medical care, military situations and
long-term space flight. Laser light and hyperbaric oxygen
have been widely acclaimed to speed wound healing in
ischemic, hypoxic wounds. An excellent review of recent
human experience with near-infrared light therapy for wound
healing was published by Conlan, et al (Conlan, 1996).
Lasers provide low energy stimulation of tissues which
results in increased cellular activity during wound healing
(Beauvoit, 1994, 1995; Eggert, 1993; Karu, 1989; Lubart,
1992, 1997; Salansky, 1998; Whelan, 1999; Yu, 1997)
including increased fibroblast proliferation, growth factor
synthesis, collagen production and angiogenesis. Lasers,
however, have some inherent characteristics that make their
use in a clinical setting problematic, such as limitations
in wavelength capabilities and beam width. The combined
wavelengths of light optimal for wound healing cannot be
efficiently produced, and the size of wounds that may be
treated by lasers is limited. Light-emitting diodes (LEDs)
offer an effective alternative to lasers. These diodes can
be made to produce multiple wavelengths, and can be arranged
in large, flat arrays allowing treatment of large wounds.
Potential benefits to NASA, military, and civilian
populations include treatment of serious burns, crush
injuries, non-healing fractures, muscle and bone atrophy,
traumatic ischemic wounds, radiation tissue damage,
compromised skin grafts, and tissue regeneration.
Combat casualty care in Special Operations
already have adopted the NASA LED technology for submarines
deployed in training with risk of injury. The USS Salt Lake
City is currently underway with an LED Array in the
Pacific. Special Operations are characterized by lightly
equipped, highly mobile troops entering situations requiring
optimal physical conditioning at all times. Wounds are an
obvious physical risk during combat operations. Any simple
and lightweight equipment that promotes wound healing and
musculoskeletal rehabilitation and conditioning has
potential merit. NASA LEDs have proven to stimulate wound
healing at near-infrared wavelengths of 680, 730 and 880 nm
in laboratory animals, and have been approved by the U.S.
Food and Drug Administration (FDA) for human trials. The
NASA LED arrays are light enough and mobile enough to have
already flown on the Space Shuttle numerous times. LED
arrays may be used for improved wound healing and treatment
of problem wounds as well as speeding the return of
deconditioned personnel to full duty performance.
Examples include:
- Promotion of the rate of muscle
regeneration after confinement or surgery.
- Personnel spending long periods of
time aboard submarines may use LED arrays to combat
muscle atrophy during relative inactivity.
- LED arrays may be introduced early to
speed wound healing in the field. Human trials have
begun at the Medical College of Wisconsin, Naval Special
Warfare Command, Submarine Squadron ELEVEN and
NASA-Marshall Space Flight Center.
Wound Healing with NASA LEDs
EXPERIMENTS USING AN ISCHEMIA ANIMAL MODEL
SYSTEM PROVIDE PRE-CLINICAL DATA RELEVANT TO HUMAN HEALING
PROBLEMS, CHRONIC NON-HEALING WOUNDS.
LED-Wound Healing in Rats
An ischemic wound is a wound in which
there is a lack of oxygen to the wound bed due to an
obstruction of arterial blood flow. Tissue ischemia is a
significant cause of impaired wound healing which renders
the wound more susceptible to infection, leading to chronic,
non-healing wounds. Despite progress in wound healing
research, we still have very little understanding of what
constitutes a chronic wound, particularly at the molecular
level, and have minimal scientific rationale for treatment.
In order to study the effects of NASA LED
technology and hyperbaric oxygen therapy (HBO), we developed
a model of an ischemic wound in normal Sprague Dawley rats.
Two parallel 11-cm incisions were made 2.5 cm apart on the
dorsum of the rats leaving the cranial and caudal ends
intact. The skin was elevated along the length of the flap
and two punch biopsies created the wounds in the center of
the flap. A sheet of silicone was placed between the skin
and the underlying muscle to act as a barrier to vascular
growth, thus increasing the ischemic insult to the wounds.
The four groups, each consisting of 15 rats, in this study
include: the control (no LED or HBO), HBO only, LED (880
nm) only, and LED and HBO in combination. The HBO was
supplied at 2.4 atm for 90 minutes, and the LED was
delivered at a fluency of 4J/cm2 for fourteen consecutive
days. A future study will incorporate the combination of
three wavelengths (670nm, 728nm, and 880nm) in the treatment
groups.
The wounds were traced manually on days 4,
7, 10, and 14. These tracings were subsequently scanned
into a computer and the size of the wounds was tracked using
Sigma Scan Pro software. Figure 1 depicts the change in
wound size over the course of the 14-day experiment. The
combination of HBO and LED (880 nm) proves to have the
greatest effect in wound healing in terms of this
qualitative assessment of wound area. At day 7, wounds of
the HBO and LED (880nm) group are 36% smaller than those of
the control group. That size discrepancy remains even by
day 10. The LED (880nm) alone also showed to speed wound
closure. On day 7, the LED (880 nm) treated wounds are 20%
smaller than the control wounds. By day 10, the difference
between these two groups has dropped to 12%. This is due to
the fact that there is a point when the wounds from all of
the groups will be closed. Hence, the early differences are
the most important in terms of determining the optimal
effects of a given treatment. This can be seen in Figure 1
at day 14 when the points are converging due to the fact
that the wounds are healing.
Analysis of the biochemical makeup of the
wounds at days 4, 7, and 14 is currently underway. The day
0 time point was determined by evaluating the punch biopsy
samples from the original surgery. The levels of basic
fibroblast growth factor (FGF-2) and vascular endothelial
growth factor (VEGF) were determined using ELISA (enzyme
linked immunosorbent assay). The changes in the VEGF
concentration throughout the 14-day experiment can be seen
in Figure 2. The LED (880 nm) group experiences a VEGF peak
at day 4 much like the control group. In contrast, the
hyperoxic effect of the HBO suppresses the day 4 peak, and
instead, the HBO groups peak at day 7. The synergistic
effect of the HBO and LED (880 nm) can be seen at day 4.
The VEGF level for the group receiving both treatments is
markedly higher at day 4 than the HBO only group. The HBO
and LED (880 nm) treated group also experiences the day 7
peak characterized by the HBO treatment. Hence, there is a
more uniform rise and fall to the VEGF level in the combined
treatment group as opposed to the sudden increases seen in
the control, LED only, and HBO only groups. By day 14, the
HBO treated groups have dropped closer to the normal level
than the LED (880 nm) only or control groups.
The synergistic effects of HBO and LED
(880 nm) can be seen easily in Figure 3. The pattern of the
changes in basic fibroblast growth factor (FGF-2)
concentration is similar to that of the VEGF data. It is
clear that the LED (880 nm) day 4 peak is higher than the
day 4 peak of the control group. These peaks can be
attributed to the hypoxic effect of the tissue ischemia
created in the surgery. The hyperoxia of the HBO therapy
has a greater effect on suppressing the FGF-2 concentration
at day 4 than the VEGF concentration at the same time
point. The synergy of the two treatments is evident when
looking at the HBO and LED (880 nm) treated group. The
concentration of FGF-2 at day 4 is significantly enhanced by
the LED (880 nm) treatment. Whereas, the level would
normally drop off by day 7 for a LED-only treated wound, the
HBO effect seizes control causing the concentration of FGF-2
to plateau. Hence, an elevated FGF-2 concentration is
achieved throughout the greater part of the 14 day treatment
with both HBO and LED (880) therapies. Further analysis of
the excised wounds will include matrix metalloproteinase 2
and 9 (MMP-2 and MMP-9) determination by ELISA, histological
examination, and RNA extraction. |
| In addition to ischemic and
chronic wound healing, we have recently begun using NASA
LEDs to promote healing of acute oral lesions in pediatric
leukemia patients. As a final life-saving effort, leukemia
patients are given healthy bone marrow from an HLA-matched
donor. Prior to the transplant, the patient is given a
lethal dose of chemo and radiation therapy in order to
destroy their own, cancerous, bone marrow. Because many
chemotherapeutic drugs as well as radiation therapy kill all
rapidly dividing cells indiscriminately, the mucosal linings
of the mouth and gastrointestinal tract are often damaged
during the treatment. As a result of these GI effects,
patients often develop ulcers in their mouths (oral
mucositis), and suffer from nausea and diarrhea. Oral
mucositis is a significant risk for this population as it
can impair the ability to eat and drink, and poses a risk
for infection in this immunocompromized patient. Because
lasers have been shown to speed healing of oral mucositis (Barasch,
et al., 1995), we have recently expanded the wound-healing
abilities of NASA LEDs to include these oral lesions.
Beginning on the day after the last dose of chemotherapy, we
treat one side of the mouth with a 688nm LED at 4J/cm2 daily
until the lesions are healed. Dental clinicians monitor the
rate of healing by using an Oral Mucositis Index (Schubert,
et al., 1992) and a Visual Analog Scale to assess mouth
pain. Although many BMT patients must receive intravenous
feeding due to their oral mucositis, all of the patients we
have treated with LEDs have been able to eat, drink, and
talk. All have had nausea, diarrhea, and sore throats,
indicating mucositis elsewhere in their GI tract, but their
oral cavities have been markedly less affected by mucosal
ulcers. This study has only included 10% of our target
subject number (3/30), and the data so far is preliminary
(figure1), but reports by the attending oncologists reveal
that these patients have developed significantly less oral
mucositis than was expected, especially Patient 2 who
received Melphalan, which is notorious for causing severe
mucositis. All patients have had Patient Controlled
Analgesia (PCA) with morphine sulfate, but all have reported
that it was not their mouths that caused them to activate
it.Further In Vitro LED Cell Growth Studies
In order to better understand the effects of
LEDs on cell growth and proliferation, we have measured
radiolabeled thymidine incorporation in vitro in several
cell lines treated with LEDs at various wavelengths and
energy levels. As previously reported (Whelan, 2000), 3T3
fibroblasts (mouse derived skin cells) responded extremely
well to LED exposure. Cell growth increased 150-200% over
untreated controls. Additionally, we have treated
osteoblasts (rat derived bone cells), and L6 rat skeletal
muscle cells with LEDs and have found that both fibroblasts
and particularly osteoblasts demonstrated a growth-phase
specificity to LED treatment, responding only when cells are
in the growth phase. In these experiments, fibroblasts and
osteoblasts at a concentration of 1x104 cells/well were
seeded in 24 well plates with a well diameter of 2 square
centimeters. DNA synthesis was determined on the second,
third and fourth days in culture for both fibroblasts
(figure 1) and osteoblasts (figure 2). Exposure to LED
irradiation accelerated the growth rate of fibroblasts and
osteoblasts in culture for 2 to 3 days (growing phase), but
showed no significant change in growth rate for cells in
culture at 4 days (stationary phase). These data are
important demonstrations of cell-cell contact inhibition,
which occurs in vitro once cell cultures approach
confluence. This is analogous in vivo to a healthy
organism, which will regenerate healing tissue, but stop
further growth when healing is complete. It is important to
demonstrate that LED treatment accelerates this normal
healing. |